Welcome to our dedicated page for Ultragenyx Pharm news (Ticker: RARE), a resource for investors and traders seeking the latest updates and insights on Ultragenyx Pharm stock.
Ultragenyx Pharmaceutical Inc. develops and commercializes therapies for serious rare and ultra-rare genetic diseases. Company news commonly covers revenue from approved medicines such as Crysvita, Dojolvi, and Mepsevii, financial guidance, and updates to a portfolio of approved therapies and product candidates for diseases with high unmet medical need and clear biology.
Recurring developments include FDA interactions and clinical data for investigational programs such as UX111 for Sanfilippo syndrome type A, GTX-102 for Angelman syndrome, UX016 for GNE myopathy, and AAV gene therapy candidates for rare metabolic disorders. Updates also include healthcare conference participation, employment inducement equity grants under Nasdaq rules, and corporate restructuring or expense-management actions when disclosed.
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced the grant of stock options totaling 14,445 shares and 4,815 restricted stock units to two newly hired employees. This grant, which took place on August 16, 2021, aligns with the company's Employment Inducement Plan and Nasdaq Listing Rule 5635(c)(4). The stock options have a ten-year term and an exercise price of $88.00 per share. Vested shares will be distributed over four years, contingent on ongoing employment. Ultragenyx continues to focus on developing therapies for rare diseases.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that CEO Emil D. Kakkis will participate in a panel discussion titled Miss Con-GENE-iality - Updates in Gene Tx at the Wedbush PacGrow Healthcare Conference on August 11, 2021, at 12:00 PM ET. The event will be accessible via live and archived webcasts on the company’s website for 90 days. Ultragenyx focuses on developing therapies for serious rare and ultra-rare genetic diseases, with a commitment to efficient drug development and addressing unmet medical needs.
Ultragenyx Pharmaceutical reported Q2 2021 total revenue of $87.0 million, reflecting a 38% increase from Q2 2020, driven by strong Crysvita sales of $44.7 million. The guidance for Crysvita remains at $180-$190 million for 2021. Dojolvi continues to gain traction with 220 patients on therapy. Operating expenses rose 36% to $169.8 million. The company expects to initiate four pivotal clinical trials in the next six months, enhancing its late-stage pipeline. As of June 30, cash and equivalents stood at $973.8 million.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) will host a conference call on August 2, 2021, at 5 PM ET to discuss its financial results for Q2 2021, ending June 30. The company is known for developing therapies for serious rare genetic diseases and has a diverse portfolio aimed at unmet medical needs. Interested participants can access the live webcast through their website or dial in by phone. This update underscores the company's commitment to efficient drug development and patient care in the rare disease sector.
Ultragenyx Pharmaceutical announced that the FDA and the European Commission have granted Orphan Drug Designation for UX053, aimed at treating Glycogen Storage Disease Type III (GSDIII), affecting over 10,000 patients in developed nations. Enrollment for a Phase 1/2 clinical trial is anticipated in late 2021, evaluating the drug's safety, tolerability, and efficacy. The Orphan Drug Designation provides significant market exclusivity benefits, including seven years in the U.S. and ten years in the EU.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced the appointment of Corsee Sanders, Ph.D., to its Board of Directors, effective June 29, 2021. Dr. Sanders brings extensive experience in global clinical development and new technologies from her previous roles at Celgene and Juno Therapeutics. CEO Emil D. Kakkis highlighted her expertise as critical for advancing ongoing clinical trials and expanding Ultragenyx's rare disease pipeline. Dr. Sanders holds degrees in statistics and has served on multiple biotechnology boards, further enhancing the company’s leadership in developing therapies for rare genetic diseases.
GeneTx and Ultragenyx have received approval from the U.K. MHRA for a Phase 1/2 clinical trial of GTX-102, an investigational treatment for Angelman syndrome. Patient enrollment is set to begin in the U.K. and Canada in the second half of 2021, with clinical data expected by year-end. Following a productive FDA meeting, GeneTx plans to submit a revised protocol to resume studies in the U.S. GTX-102 has shown clinical activity in initial patients, and the new trial design aims to improve safety through repeated lower dosing. This therapy addresses a significant unmet medical need.
Ultragenyx Pharmaceutical (NASDAQ: RARE) will have CEO Emil D. Kakkis present at the Goldman Sachs 42nd Annual Healthcare Conference on June 10, 2021, at 3:00 PM ET. The presentation will be available via a live and archived webcast on the company’s website, accessible for 90 days following the event.
Ultragenyx is focused on developing therapies for serious rare genetic diseases and has a diverse portfolio aimed at addressing high unmet medical needs.
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced that CEO Emil D. Kakkis will present at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 4:30 PM ET. The event will be accessible via live and archived webcast on the company’s website, with a replay available for 90 days. Ultragenyx specializes in developing therapies for serious rare and ultra-rare genetic diseases and aims to provide safe and effective treatments efficiently.
GeneTx Biotherapeutics and Ultragenyx Pharmaceutical have received Health Canada clearance to enroll patients in a Phase 1/2 study of GTX-102, an investigational treatment for Angelman syndrome. Expected to begin in early 2021, the study will evaluate the safety and tolerability of GTX-102 in pediatric patients. The trial includes two cohorts, enrolling approximately 12 patients aged 4 to 17 years. The first patient in Canada is set to be enrolled in the second half of 2021, with preliminary clinical data anticipated before year-end.